24th Apr 2015 10:27
Director Declaration
LONDON, UK, 24 April 2015 - Skyepharma PLC (LSE SKP), the expert oral and inhalation drug development company, today announces that John Biles, a Non-Executive Director of the Company, has stepped down as a Non-Executive Director of Bodycote plc at the conclusion of Bodycote's Annual General Meeting held on 23 April 2015.
This information is disclosed to the London Stock Exchange in accordance with the requirements under paragraph 9.6.14R of the United Kingdom Listing Rules relating to the disclosure of changes in the existing directorships in publically quoted companies by a Director of the Company.
For further information please contact:
Skyepharma PLC | |
Peter Grant, Chief Executive Officer Andrew Derodra, Chief Financial Officer | +44 (0)20 7881 0524 |
Jonathan Birt, Investor and Media Relations | +44 (0)7860 361746 |
About Skyepharma PLC
Skyepharma combines proven scientific expertise with validated proprietary technologies to develop innovative oral and inhalation pharmaceutical products. The Group's licenses cover 16 approved inhalation, oral, topical and injectable products, which generate milestones, recurring royalties, and in some cases, product supply revenues. The Group also earns milestones and contract development revenues from new product developments. Products developed by Skyepharma are marketed by some of the world's most respected pharmaceutical companies. For more information, visit www.skyepharma.com.
Related Shares:
SKP.L